Brooks Laboratories Ltd (BROOKS) is currently trading at 58.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Brooks Laboratories Limited is an India-based pharmaceutical manufacturer and contract development and manufacturing organization (CDMO) focused on formulations across tablets, dry syrups, general and liquid injections, dry powder injections, eye/ear drops, oncology and hormonal injectables, operating primary manufacturing at Baddi and a dedicated EU-certified facility at Vadodara. Financially, Brooks reported standalone revenue of Rs. 8,573.84 lakhs for FY2026 and a standalone profit before tax of Rs. 580.50 lakhs, whereas consolidated results were materially stronger with consolidated profit before tax of Rs. 2,458.35 lakhs, reflecting the large contribution from its jointly controlled entity in the period. A key strategic driver is the jointly controlled Brooks Steriscience Limited whose licensing income and profit share powered consolidated earnings: Brooks Steriscience recorded licensing income and profit that translated into a Rs. 1,877.85 lakhs share of profit for Brooks Laboratories in FY2026, underpinning consolidated profitability and export-market access. Balance sheet signals include sizeable financial investments of about Rs. 9,052.81 lakhs, cash and cash equivalents of Rs. 658.79 lakhs at year-end, recent capex and CWIP of Rs. 350.57 lakhs and Rs. 119.06 lakhs respectively, and a prior-year preferential allotment that raised approximately Rs. 4,250.43 lakhs, while deferred tax assets on carried forward losses remain unrecognised.

Over the past 52 weeks, Brooks Laboratories Ltd has traded between a low of ₹36.90 and a high of ₹119.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Brooks Laboratories Ltd has a market capitalization of approximately 170.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Brooks Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.94 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 170.91 Cr, Brooks Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Brooks Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Brooks Laboratories Ltd is 12.94. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

It approved the sale of 51,220 equity shares held in Brooks Steriscience Limited to Steriscience Specialties Private Limited.